Therapeutics & Pipeline

Deuruxolitinib Hit 31% SALT≤20 at Week 24, But Roundtable Warns on Cross-Trial Math

<![CDATA[Weighing Cross-Trial Data and Patient Timelines in Alopecia Areata Treatment]]>
sasint / pixabay

Pooled data from THRIVE-AA1 and THRIVE-AA2 show 31.0% of patients on deuruxolitinib reached a SALT score of 20 or less at week 24, against 0.8% on placebo — but clinicians at a Dermatology Times Case-Based Roundtable in Atlanta, Georgia, were told not to stack those numbers against rival trials. Jessica Mercer, MD, dermatologist, co-managing partner and director of dermatopathology at Georgia Dermatology Partners, moderated the program, titled “Alopecia Areata in Practice: Individualizing Care Through Patient Cases.” Dermatologists, nurse practitioners and physician assistants worked through 3 cases covering the 3 FDA-approved JAK inhibitors for severe disease: deuruxolitinib (Leqselvi; Sun Pharmaceutical Industries), ritlecitinib (Litfulo; Pfizer) and baricitinib (Olumiant; Eli Lilly).

When should clinicians escalate to systemic therapy?

The first case involved a 33-year-old man with 45% scalp hair loss, minimal response to 4 months of topical corticosteroid, and a wedding in 6 months. In a poll, 47% of attendees named extent of scalp involvement as the top trigger for systemic escalation; 41% named psychosocial or quality-of-life impact.

Mercer favors the Alopecia Areata Scale over the Severity of Alopecia Tool (SALT) alone, because secondary criteria — eyebrow or eyelash involvement, rapid progression — can move a patient into a higher severity category. Attendees backed a cautiously optimistic message on timing, paired with a backup plan such as camouflage. “Underpromise and overdeliver,” one attendee said. Speed of response drove choices too: 69% of polled attendees called it extremely influential in treatment selection.

Why the trial numbers don't compare

In BRAVE-AA1, 22% of patients on baricitinib 2 mg and 38.8% on 4 mg reached SALT 20 or less — but at week 36, not week 24. Mercer cautioned against comparing figures across trials, citing differences in endpoints, enrolled populations and permitted adjunctive therapy.

“Looking at the exclusion criteria has been massive,” an attendee said. Some attendees reported mixed results with deuruxolitinib in adults; others described baricitinib as slow. “It’s a slow burn,” one said.

Payer requirements to start baricitinib at 2 mg drew criticism for patients with a defined timeline. “Why am I going to waste one of those months on a lower-dose medication?” an attendee asked.

How do patient-reported outcomes track response?

The second case featured a 29-year-old woman whose scalp hair loss rose from 21% to 36% in 3 months, with significant anxiety and no eyebrow or eyelash involvement. Attendees classified her as moderate by objective criteria, though one noted a possible ophiasis pattern. All supported systemic therapy.

Mercer reviewed patient-reported outcome tools, including Skindex-16 and the Hospital Anxiety and Depression Scale (HADS). In an observational study of baricitinib, Skindex-16 scores fell from 57.1 to 30 at 48 weeks; in a ritlecitinib study, they fell from 48.4 to 30.9 at 24 weeks.

“These medications, they are not just growth stimulants; they’re antidepressants,” Mercer said. One attendee asks patients to show their hairstylist photos at each visit. “Hairstylists also double as therapists too,” the attendee said.

Mercer waits about 6 months before judging response, based on trial durations. In a poll, 75% of attendees said they would switch to another JAK inhibitor after an inadequate response. Mercer said she would first add an adjunct such as oral minoxidil. “We have a wallet of options, not a bag of options,” she said.

What does baseline workup and monitoring require?

The third case involved a 42-year-old man with 85% scalp hair loss and new eyebrow and beard involvement. His CYP2C9 genotype indicated a normal metabolizer, and baseline CBC, hepatitis screening and TB screening were unremarkable. In a poll, 69% of attendees said the CYP2C9 result only rules a patient in or out for deuruxolitinib.

Mercer explains the test to patients as a glimpse into side effect risk. One attendee reported a 3-week turnaround; attendees flagged the lack of an in-office lab as a barrier.

On lab scheduling, Mercer once checked at baseline and at 1, 3 and 6 months, but now checks at baseline and 6 months, with earlier testing for older patients. Attendees also discussed zoster vaccination for adults starting a JAK inhibitor.

Safety data horizons differ across agents: Mercer noted deuruxolitinib data covered 24 weeks, while ritlecitinib and baricitinib data extend to 3 years. She frames boxed-warning discussions by screening for personal and family history first. “So you want to explain, not excuse,” Mercer said.

In the first year she sees patients at 3 and 6 months, then roughly every 6 months while disease is stable.

Where does the field go from here?

In a final poll, 12 of 33 selections indicated attendees already felt comfortable with JAK inhibitors; practical guidance on testing and patient selection and best practices for monitoring each drew 6 selections. As 3-year safety data for ritlecitinib and baricitinib accumulate and deuruxolitinib's real-world track record builds, expect the debate over sequencing, adjuncts and payer-imposed dose ladders to sharpen.

Source: dermatologytimes.com

Share this article:

Tom Whitfield

Show full bio

Senior reporter covering companies, deals and strategy in Clinical dermatology, inflammatory skin disease and biologics at Derm Field.

More from Tom Whitfield →

Related articles

« Previous articleNext article »